- Home
- AUC vs MNOV Comparison
AUC vs MNOV Comparison
Compare AUC & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUC | MNOV |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | 6 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.1M | 67.9M |
| IPO Year | 2019 | 2004 |
Fundamental Metrics
Financial Performance| Metric | AUC | MNOV |
|---|---|---|
| Price | $7.19 | $1.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 4.9K | ★ 37.0K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $180.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $5.82 | $1.17 |
| 52 Week High | $8.58 | $1.96 |
Technical Indicators
Market Signals| Indicator | AUC | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 52.52 | 47.47 |
| Support Level | $7.06 | $1.30 |
| Resistance Level | $8.54 | $1.46 |
| Average True Range (ATR) | 0.52 | 0.04 |
| MACD | -0.15 | -0.00 |
| Stochastic Oscillator | 54.39 | 33.33 |
Price Performance
Historical ComparisonAbout AUC ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial consulting services to small and medium-sized enterprises. It operates in one operating segment, which is the consulting service business. The company prominently generated revenues from consulting services to its clients. Geographically, the maximum revenue is derived from Hong Kong.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.